Cargando…
Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB
Extracellular lysyl oxidases (LOX and LOXL1–LOXL4) are critical for collagen biosynthesis. LOXL2 is a marker of poor survival in oral squamous cell cancer. We investigated mechanisms by which tumor cell secreted LOXL2 targets proximal mesenchymal cells to enhance tumor growth and metastasis. This st...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513832/ https://www.ncbi.nlm.nih.gov/pubmed/31086173 http://dx.doi.org/10.1038/s41389-019-0144-0 |
_version_ | 1783417771587010560 |
---|---|
author | Mahjour, Faranak Dambal, Vrinda Shrestha, Neha Singh, Varun Noonan, Vikki Kantarci, Alpdogan Trackman, Philip C. |
author_facet | Mahjour, Faranak Dambal, Vrinda Shrestha, Neha Singh, Varun Noonan, Vikki Kantarci, Alpdogan Trackman, Philip C. |
author_sort | Mahjour, Faranak |
collection | PubMed |
description | Extracellular lysyl oxidases (LOX and LOXL1–LOXL4) are critical for collagen biosynthesis. LOXL2 is a marker of poor survival in oral squamous cell cancer. We investigated mechanisms by which tumor cell secreted LOXL2 targets proximal mesenchymal cells to enhance tumor growth and metastasis. This study identified the first molecular mechanism for LOXL2 in the promotion of cancer via its enzymatic modification of a non-collagenous substrate in the context of paracrine signaling between tumor cells and resident fibroblasts. The role and mechanism of active LOXL2 in promoting oral cancer was evaluated and employed a novel LOXL2 small molecule inhibitor, PSX-S1C, administered to immunodeficient, and syngeneic immunocompetent orthotopic oral cancer mouse models. Tumor growth, histopathology, and metastases were monitored. In vitro mechanistic studies with conditioned tumor cell medium treatment of normal human oral fibroblasts were carried out in the presence and absence of the LOXL2 inhibitor to identify signaling mechanisms promoted by LOXL2 activity. Inhibition of LOXL2 attenuated cancer growth and lymph node metastases in the orthotopic tongue mouse models. Immunohistochemistry data indicated that LOXL2 expression in and around tumors was decreased in mice treated with the inhibitor. Inhibition of LOXL2 activity by administration of PXS-S1C to mice reduced tumor cell proliferation, accompanied by changes in morphology and in the expression of epithelial to mesenchymal transition markers. In vitro studies identified PDGFRβ as a direct substrate for LOXL2, and indicated that LOXL2 and PDGF-AB together secreted by tumor cells optimally activated PDGFRβ in fibroblasts to promote proliferation and the tendency toward fibrosis via ERK activation, but not AKT. Optimal fibroblast proliferation in vitro required LOXL2 activity, while tumor cell proliferation did not. Thus, tumor cell-derived LOXL2 in the microenvironment directly targets neighboring resident cells to promote a permissive local niche, in addition to its known role in collagen maturation. |
format | Online Article Text |
id | pubmed-6513832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-65138322019-07-18 Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB Mahjour, Faranak Dambal, Vrinda Shrestha, Neha Singh, Varun Noonan, Vikki Kantarci, Alpdogan Trackman, Philip C. Oncogenesis Article Extracellular lysyl oxidases (LOX and LOXL1–LOXL4) are critical for collagen biosynthesis. LOXL2 is a marker of poor survival in oral squamous cell cancer. We investigated mechanisms by which tumor cell secreted LOXL2 targets proximal mesenchymal cells to enhance tumor growth and metastasis. This study identified the first molecular mechanism for LOXL2 in the promotion of cancer via its enzymatic modification of a non-collagenous substrate in the context of paracrine signaling between tumor cells and resident fibroblasts. The role and mechanism of active LOXL2 in promoting oral cancer was evaluated and employed a novel LOXL2 small molecule inhibitor, PSX-S1C, administered to immunodeficient, and syngeneic immunocompetent orthotopic oral cancer mouse models. Tumor growth, histopathology, and metastases were monitored. In vitro mechanistic studies with conditioned tumor cell medium treatment of normal human oral fibroblasts were carried out in the presence and absence of the LOXL2 inhibitor to identify signaling mechanisms promoted by LOXL2 activity. Inhibition of LOXL2 attenuated cancer growth and lymph node metastases in the orthotopic tongue mouse models. Immunohistochemistry data indicated that LOXL2 expression in and around tumors was decreased in mice treated with the inhibitor. Inhibition of LOXL2 activity by administration of PXS-S1C to mice reduced tumor cell proliferation, accompanied by changes in morphology and in the expression of epithelial to mesenchymal transition markers. In vitro studies identified PDGFRβ as a direct substrate for LOXL2, and indicated that LOXL2 and PDGF-AB together secreted by tumor cells optimally activated PDGFRβ in fibroblasts to promote proliferation and the tendency toward fibrosis via ERK activation, but not AKT. Optimal fibroblast proliferation in vitro required LOXL2 activity, while tumor cell proliferation did not. Thus, tumor cell-derived LOXL2 in the microenvironment directly targets neighboring resident cells to promote a permissive local niche, in addition to its known role in collagen maturation. Nature Publishing Group UK 2019-05-13 /pmc/articles/PMC6513832/ /pubmed/31086173 http://dx.doi.org/10.1038/s41389-019-0144-0 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Mahjour, Faranak Dambal, Vrinda Shrestha, Neha Singh, Varun Noonan, Vikki Kantarci, Alpdogan Trackman, Philip C. Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB |
title | Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB |
title_full | Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB |
title_fullStr | Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB |
title_full_unstemmed | Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB |
title_short | Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB |
title_sort | mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with pdgf-ab |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513832/ https://www.ncbi.nlm.nih.gov/pubmed/31086173 http://dx.doi.org/10.1038/s41389-019-0144-0 |
work_keys_str_mv | AT mahjourfaranak mechanismfororaltumorcelllysyloxidaselike2incancerdevelopmentsynergywithpdgfab AT dambalvrinda mechanismfororaltumorcelllysyloxidaselike2incancerdevelopmentsynergywithpdgfab AT shresthaneha mechanismfororaltumorcelllysyloxidaselike2incancerdevelopmentsynergywithpdgfab AT singhvarun mechanismfororaltumorcelllysyloxidaselike2incancerdevelopmentsynergywithpdgfab AT noonanvikki mechanismfororaltumorcelllysyloxidaselike2incancerdevelopmentsynergywithpdgfab AT kantarcialpdogan mechanismfororaltumorcelllysyloxidaselike2incancerdevelopmentsynergywithpdgfab AT trackmanphilipc mechanismfororaltumorcelllysyloxidaselike2incancerdevelopmentsynergywithpdgfab |